Literature DB >> 22142442

Caregiver and adult patient perspectives on the importance of a diagnosis of 22q11.2 deletion syndrome.

G Costain1, E W C Chow, P N Ray, A S Bassett.   

Abstract

BACKGROUND: Recent advances in genetics are particularly relevant in the field of intellectual disability (ID), where sub-microscopic deletions or duplications of genetic material are increasingly implicated as known or suspected causal factors. Data-driven reports on the impact of providing an aetiological explanation in ID are needed to help justify widespread use of new and expensive genetic technologies.
METHODS: We conducted a survey of caregivers on the value of a genetic/aetiologic diagnosis of 22q11.2 deletion syndrome (22q11.2DS), the most common microdeletion syndrome in ID. We also surveyed the opinion of a high-functioning subset of adults with 22q11.2DS themselves. We used standard quantitative and qualitative methods to analyse the responses.
RESULTS: In total, 73 of 118 surveys were returned (61.9%). There was convergence of quantitative and qualitative results, and consistency between adult patient and caregiver responses. A definitive molecular diagnosis of 22q11.2DS was a critical event with diverse positive repercussions, even if occurring later in life. Frequently cited benefits included greater understanding and certainty, newfound sense of purpose and a platform for advocacy, and increased opportunities to optimise medical, social and educational needs.
CONCLUSIONS: This is the first study to characterise the impact of a diagnosis of this representative microdeletion syndrome on adult patients and their families. The results both validate and expand on the theoretical benefits proposed by clinicians and researchers. The use of genome-wide microarray technologies will provide an increasing number of molecular diagnoses. The importance of a diagnosis of 22q11.2DS demonstrated here therefore has implications for changing attitudes about molecular genetic diagnosis that could benefit individuals with ID of currently unknown cause and their families.
© 2011 The Authors. Journal of Intellectual Disability Research © 2011 Blackwell Publishing Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 22142442      PMCID: PMC4459829          DOI: 10.1111/j.1365-2788.2011.01510.x

Source DB:  PubMed          Journal:  J Intellect Disabil Res        ISSN: 0964-2633


  47 in total

Review 1.  Copy number variations in schizophrenia: critical review and new perspectives on concepts of genetics and disease.

Authors:  Anne S Bassett; Stephen W Scherer; Linda M Brzustowicz
Journal:  Am J Psychiatry       Date:  2010-05-03       Impact factor: 18.112

2.  A question of benefit.

Authors: 
Journal:  Nat Genet       Date:  2010-10       Impact factor: 38.330

3.  Clinically detectable copy number variations in a Canadian catchment population of schizophrenia.

Authors:  Anne S Bassett; Gregory Costain; Wai Lun Alan Fung; Kathryn J Russell; Laura Pierce; Ronak Kapadia; Ronald F Carter; Eva W C Chow; Pamela J Forsythe
Journal:  J Psychiatr Res       Date:  2010-11       Impact factor: 4.791

4.  Response to Verri et al. ( Journal of Intellectual Disability Research 48, 679-686): is there room for hope when considering the problem of late diagnosis in intellectual disability?

Authors:  A Henderson; M Dick
Journal:  J Intellect Disabil Res       Date:  2005-09

5.  It does matter: the importance of making the diagnosis of a genetic syndrome.

Authors:  Nathaniel H Robin
Journal:  Curr Opin Pediatr       Date:  2006-12       Impact factor: 2.856

6.  Recognizing a common genetic syndrome: 22q11.2 deletion syndrome.

Authors:  Ronak K Kapadia; Anne S Bassett
Journal:  CMAJ       Date:  2008-02-12       Impact factor: 8.262

Review 7.  Mental health: knowledge, attitudes and training of professionals on dual diagnosis of intellectual disability and psychiatric disorder.

Authors:  S Werner; M Stawski
Journal:  J Intellect Disabil Res       Date:  2011-05-10

Review 8.  Consensus statement: chromosomal microarray is a first-tier clinical diagnostic test for individuals with developmental disabilities or congenital anomalies.

Authors:  David T Miller; Margaret P Adam; Swaroop Aradhya; Leslie G Biesecker; Arthur R Brothman; Nigel P Carter; Deanna M Church; John A Crolla; Evan E Eichler; Charles J Epstein; W Andrew Faucett; Lars Feuk; Jan M Friedman; Ada Hamosh; Laird Jackson; Erin B Kaminsky; Klaas Kok; Ian D Krantz; Robert M Kuhn; Charles Lee; James M Ostell; Carla Rosenberg; Stephen W Scherer; Nancy B Spinner; Dimitri J Stavropoulos; James H Tepperberg; Erik C Thorland; Joris R Vermeesch; Darrel J Waggoner; Michael S Watson; Christa Lese Martin; David H Ledbetter
Journal:  Am J Hum Genet       Date:  2010-05-14       Impact factor: 11.025

9.  Why do we need a diagnosis? A qualitative study of parents' experiences, coping and needs, when the newborn child is severely disabled.

Authors:  A H Graungaard; L Skov
Journal:  Child Care Health Dev       Date:  2007-05       Impact factor: 2.508

10.  Living with a child at risk for psychotic illness: the experience of parents coping with 22q11 deletion syndrome: an exploratory study.

Authors:  Laura Hercher; Georgette Bruenner
Journal:  Am J Med Genet A       Date:  2008-09-15       Impact factor: 2.802

View more
  20 in total

1.  Pathogenic rare copy number variants in community-based schizophrenia suggest a potential role for clinical microarrays.

Authors:  Gregory Costain; Anath C Lionel; Daniele Merico; Pamela Forsythe; Kathryn Russell; Chelsea Lowther; Tracy Yuen; Janice Husted; Dimitri J Stavropoulos; Marsha Speevak; Eva W C Chow; Christian R Marshall; Stephen W Scherer; Anne S Bassett
Journal:  Hum Mol Genet       Date:  2013-06-27       Impact factor: 6.150

Review 2.  Genetics of Childhood-onset Schizophrenia 2019 Update.

Authors:  Jennifer K Forsyth; Robert F Asarnow
Journal:  Child Adolesc Psychiatr Clin N Am       Date:  2019-10-17

3.  Disclosure of psychiatric manifestations of 22q11.2 deletion syndrome in medical genetics: A 12-year retrospective chart review.

Authors:  Serena Talcott Baughman; Emily Morris; Kimberly Jensen; Jehannine Austin
Journal:  Am J Med Genet A       Date:  2015-05-31       Impact factor: 2.802

4.  High Rates of Genetic Diagnosis in Psychiatric Patients with and without Neurodevelopmental Disorders: Toward Improved Genetic Diagnosis in Psychiatric Populations.

Authors:  Joyce So; Venuja Sriretnakumar; Jessica Suddaby; Brianna Barsanti-Innes; Hanna Faghfoury; Timothy Gofine
Journal:  Can J Psychiatry       Date:  2020-06-04       Impact factor: 4.356

5.  The ever-evolving concept of clinical significance and the potential for sins of omission in genetic research.

Authors:  Gregory Costain; Anne S Bassett
Journal:  Am J Bioeth       Date:  2012       Impact factor: 11.229

6.  Elucidating the diagnostic odyssey of 22q11.2 deletion syndrome.

Authors:  Lisa D Palmer; Nancy J Butcher; Erik Boot; Kathleen A Hodgkinson; Tracy Heung; Eva W C Chow; Alina Guna; T Blaine Crowley; Elaine Zackai; Donna M McDonald-McGinn; Anne S Bassett
Journal:  Am J Med Genet A       Date:  2018-04       Impact factor: 2.802

7.  Genetic counseling, activism and 'genotype-first' diagnosis of developmental disorders.

Authors:  Daniel Navon
Journal:  J Genet Couns       Date:  2012-07-21       Impact factor: 2.537

8.  Evaluating genetic counseling for individuals with schizophrenia in the molecular age.

Authors:  Gregory Costain; Mary Jane Esplen; Brenda Toner; Stephen W Scherer; Wendy S Meschino; Kathleen A Hodgkinson; Anne S Bassett
Journal:  Schizophr Bull       Date:  2012-12-12       Impact factor: 9.306

9.  Communication of Psychiatric Risk in 22q11.2 Deletion Syndrome: A Pilot Project.

Authors:  Sarah J Hart; Kelly Schoch; Vandana Shashi; Nancy Callanan
Journal:  J Genet Couns       Date:  2015-11-18       Impact factor: 2.537

10.  A tale worth telling: the impact of the diagnosis experience on disclosure of genetic disorders.

Authors:  J Goodwin; K Schoch; V Shashi; S R Hooper; O Morad; M Zalevsky; D Gothelf; L E Campbell
Journal:  J Intellect Disabil Res       Date:  2014-07-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.